Consultant in Paediatric and TYA Oncology (sarcoma and rare-tumours), University College Hospitals NHS Foundation Trust, London, UK
United Kingdom
Dr. Ajla Tasleem Wasti is a leading pediatric oncologist specializing in sarcomas and rare tumors, with expertise in cutting-edge treatments and translational research. Currently a Consultant at University College Hospitals NHS Foundation Trust in London, she is actively involved in pediatric drug development and advanced care for young cancer patients. Dr. Wasti holds an MSc from the University of Oxford and is completing an MD(Res) at the Institute of Cancer Research. She has conducted significant research on molecular profiling and targeted therapies for pediatric cancers, with her work presented at major international conferences. Additionally, Dr. Wasti is a dedicated educator and mentor, shaping the future of pediatric oncology.
Dr. Ajla Tasleem Wasti is a highly accomplished pediatric oncologist specializing in sarcomas and rare tumors, with a significant focus on the latest therapeutic advancements and translational research. After earning her MBBS from Shifa College of Medicine, she pursued an MSc in Experimental and Translational Therapeutics from the University of Oxford and is currently completing an MD(Res) at the Institute of Cancer Research in Sutton, UK. Dr. Wasti's comprehensive training includes residencies in Pediatrics at Oklahoma University and a fellowship in Pediatric Hematology and Oncology at the University of Texas Southwestern Medical Center. Her expertise in pediatric oncology has been further honed through multiple consultant roles across leading institutions in the US, UK and Pakistan.
Currently a Consultant in Pediatric and TYA Oncology at University College Hospitals NHS Foundation Trust in London, Dr. Wasti focuses on sarcomas and rare tumors, delivering cutting-edge care for young patients. Her clinical roles are complemented by her leadership in early-phase drug development and pediatric sarcoma treatment protocols, most notably through her work at The Royal Marsden NHS Foundation Trust. Her commitment to advancing care is evident in her involvement with international groups such as the European Paediatric Soft Tissue Sarcoma Group and the British Sarcoma Group, where she contributes to research and treatment strategies for childhood cancers.
Dr. Wasti's research contributions in pediatric oncology are widely recognized. She has led and co-authored numerous studies on molecular profiling, targeted therapies, and treatment outcomes for pediatric sarcomas and neuro-oncological conditions. Her recent work includes studies on CAR-T cell trials in pediatric solid tumors and the role of radiologic response in predicting outcomes in relapsed rhabdomyosarcoma. Through collaborations with leading oncology researchers, she has presented her findings at major international conferences such as the International Symposium on Pediatric Neuro-Oncology and the European Society for Paediatric Oncology.
In addition to her research and clinical work, Dr. Wasti is deeply invested in medical education and mentorship. She has received multiple teaching awards, reflecting her dedication to training the next generation of pediatric oncologists. As a clinical supervisor and mentor, she continues to shape the careers of pediatric oncology residents and fellows at leading institutions, further solidifying her role as a key figure in the field of pediatric oncology and rare tumor research.
University College Hospitals NHS Foundation Trust, London, UK
Seattle Children’s Hospital and University of Washington
The Royal Marsden NHS Foundation Trust, Sutton, UK
Great Ormond Street Hospital for Children, London, UK
The Royal Marsden NHS Foundation Trust, Sutton, UK
University of Texas Southwestern Medical Center/Children’s Medical Center, Dallas
Oklahoma University Health Sciences Center/OU Children’s Hospital, Oklahoma City, OK
American Board of Pediatrics
2015
American Board of Pediatrics
2014
Childrens Cancer and Leukaemia Group, UK- member VIVO biobank subgroup (2020)
European Paediatric Soft tissue Sarcoma Group (EpSSG), Phase 1 and 2 subcomittee (2020)